Showing 1991-2000 of 3038 results for "".
- NovaBay Pharmaceuticals Announces Investments of $5 Million to Support US Avenova Commercialization Strategyhttps://modernod.com/news/novabay-pharmaceuticals-announces-investments-of-5-million-to-support-us-avenova-commercialization-strategy/2476424/NovaBay Pharmaceuticals announced investments totaling $5 million to support the recent strategic shift in its US commercialization strategy aimed at driving growth in Avenova sales while maintaining cost effectiveness. The investments include a convertible loan of $2 million from Ascendia
- Novartis Plans for Alcon Spin-Off on April 9, 2019https://modernod.com/news/novartis-plans-for-alcon-spin-off-on-april-9-2019/2476408/Novartis confirmed that conditions needed for the 100% spin-off of the Alcon eye care business have been met, and the spinoff is expected to be completed on April 9, 2019. Each Novartis shareholder will receive 1 Alcon share for every 5 Novartis shares/American Deposit
- Major League Soccer All-Star Alecko Eskandarian to Speak at Annual NORA Conferencehttps://modernod.com/news/major-league-soccer-all-star-alecko-eskandarian-to-speak-at-annual-nora-conference/2476364/Two-time Major League Soccer (MLS) All-Star Alecko Eskandarian will be the key-note speaker at the Neuro-Optometric Rehabilitation Association, International (NORA) 28th annual General Conference (September 21-22) at the Embassy Suites by Hilton Scottsdale Resorts, Scottsdale, Arizona.
- Novartis Issues Summary Financial Information for the Alcon Eye Care Business Ahead of Shareholder Votehttps://modernod.com/news/novartis-issues-summary-financial-information-for-the-alcon-eye-care-business-ahead-of-shareholder-vote/2476260/Novartis today published certain key financial information for the Alcon eye care business covering the full year 2018 ahead of a vote on the proposed 100% spin-off of Alcon at the Novartis Annual General Meeting of Shareholders (AGM) on February 28, 2019. The issuance of the short form fi
- Oyster Point Raises $93 Million to Support the Clinical Development of Novel Treatment for Dry Eye Diseasehttps://modernod.com/news/oyster-point-raises-93-million-to-support-the-clinical-development-of-novel-treatment-for-dry-eye-disease/2476261/Oyster Point Pharma announced a $93 million Series B financing to support the development of its product portfolio for dry eye disease, explore new treatment areas, and add key talent. The company’s lead product candidates, OC-01 and OC-02, are delivered via an ocular surface-sparing nasal
- AbbVie’s Humira (Adalimumab) Approved by Health Canada to Treat Pediatric Patients with Chronic Noninfectious Anterior Uveitishttps://modernod.com/news/abbvies-humira-adalimumab-approved-by-health-canada-to-treat-pediatric-patients-with-chronic-noninfectious-anterior-uveitis/2476279/AbbVie announced that Health Canada has approved Humira (adalimumab) for the treatment of chronic noninfectious anterior uveitis in pediatric patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropr
- College of Optometrists in Vision Development & NORA Issue Joint Recommendation for Optometric Evaluation Following Brain Injuryhttps://modernod.com/news/college-of-optometrists-in-vision-development-nora-issue-joint-recommendation-for-optometric-evaluation-following-brain-injury/2476285/The College of Optometrists in Vision Development (COVD) and the Neuro Optometric Rehabilitation Association (NORA) issued a joint call-to-action to all healthcare professionals to consider the need for medical and/or functional optometric rehabilitation services for patients who have suffered a
- Registration Now Open for Neuro-Optometric Rehabilitation Association Meetinghttps://modernod.com/news/registration-now-open-for-neuro-optometric-rehabilitation-association-meeting/2476291/Registration is now open for the Neuro-Optometric Rehabilitation Association, International (NORA) Clinical Skills Pre-Conference (September 19-20) and 28th annual General Conference (September 21-22) at the Embassy Suites by Hilton Scottsdale Resorts, Scottsdale, Arizona. The
- Melt Pharmaceuticals Improves Patent Estate for Sublingual Non-Opioid Pain and Sedation Formulationshttps://modernod.com/news/melt-pharmaceuticals-improves-patent-estate-for-sublingual-non-opioid-pain-and-sedation-formulations/2476298/Melt Pharmaceuticals, a specialty pharmaceutical company recently deconsolidated from Harrow Health, announced the U.S. Patent and Trademark office has issued two additional patents covering the company’s innovative sublingual, non-opioid pain and sedation formulations. U.S. Patents 10,16
- CVP Partners With Northwest and Central Ohio Ophthalmology Practicehttps://modernod.com/news/cvp-partners-with-northwest-and-central-ohio-ophthalmology-practice/2476202/CEI Vision Partners (CVP) announced that Retina Vitreous Associates (RVA) of Toledo, Ohio is now the newest partner practice to join the CVP platform. RVA is a vitreoretinal surgical practice with nine ophthalmologists who specialize in medical and surgical